Purpose of review Calcium is an essential ion for the maintenance of normal bone health and physiologic functions. The extracellular and intracellular levels of calcium are maintained through hormonal regulation called homeostasis. Balance, the net intake minus excretion of calcium, is maintained by hormonal regulation of intestinal absorption and fecal/urinary excretion. Homeostasis and balance are disconnected in patients with chronic kidney disease (CKD). The purpose of this review is to understand how calcium homeostasis and balance are impaired in CKD.
INTRODUCTION

Calcium homeostasis versus balance
Calcium homeostasis refers to the processes by which blood and intracellular calcium levels are regulated. The intracellular calcium level is maintained in a very narrow range, as changes in these levels are important for cell signaling, mitochondrial function, and gene transcription. Similarly, the ratio of extracellular (intravascular) calcium levels to intracellular calcium is critical in membrane potential which is key in cardiomyocyte and skeletal muscle contractility. In contrast, calcium balance refers to the net calcium intake minus total calcium output. In an ideal situation, homeostasis and balance are interconnected such that the process of homeostasis responds appropriately to maintain appropriate balance. However, in the setting of chronic kidney disease (CKD), abnormal renal handling of calcium, hormonal dysregulation, and exogenous intake of pharmacologic treatments alter both calcium homeostasis and balance. Thus, homeostasis and balance must be considered separately to understand the overall calcium health of CKD patients. Importantly, blood levels of calcium never predict calcium balance, and calcium balance is disassociated with blood levels of calcium such that balance cannot be determined from calcium blood levels. Thus, in the present review, we describe blood calcium level measurement, calcium homeostasis, and calcium balance separately.
Measurement of calcium levels in blood
The goal of calcium homeostasis is to maintain blood levels of calcium at appropriate levels for physiologic function. The assessment of calcium measurement of blood calcium levels is limited by the fact that less than 1% is located in the extravascular space and that the total calcium measured in blood samples reflects both the physiologically active ionized calcium and that calcium bound to other anions and albumin. On the contrary, the formulas for 'correcting' calcium are notoriously inaccurate in CKD [1] and in hemodialysis patients [1] in part due to differences in albumin assays [2] .
The primary regulator of calcium levels is the calcium sensing receptor (CaSR) located on tissues with involvement in calcium handling including parathyroid (PTH) glands, bone, kidney, and many others. In health, the CaSR allows for minute-tominute regulation of calcium levels. In the PTH gland, normal or high calcium levels lead to the CaSR-induced cell signaling that keeps the prepackaged PTH in an 'do not release' setting. When the blood levels of ionized calcium drop, PTH is released [3] . The CASR gene is a member of the super-family of G-protein-coupled receptors. Over 400 mutations in the gene have been identified throughout the receptor (http://www.casrdb.mcgill.ca/web site). The more severe phenotypes of autosomal dominant familial hypocalciuric hypercalcemia and autosomal recessive neonatal severe hyperparathyroidism are due to inactivating mutations; activating mutations can lead to autosomal dominant hypocalcemia (reviewed in [4] ). Single-nucleotide polymorphisms (SNPs) in the CaSR gene were responsible for 16.5% of the variance in serum ionized calcium in an Italian cohort [5] . In one genome-wide association study, the SNP rs1801725 was associated with 1.26% of the serum calcium variance in European Americans [6] . Our group also found this same SNP to be associated with serum calcium and baseline PTH in dialysis patients of European American ancestry using patients from The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events Trial [7] . Thus, genetics play an important role in determining an individual's 'normal' calcium level.
There are multiple studies identifying associations of serum calcium levels with outcomes in CKD. Some, but not all, studies have identified both low and high calcium levels associated with mortality in patients on dialysis [8] [9] [10] [11] [12] . A recent study demonstrated that higher calcium in the pre-end stage renal disease (ESRD) period was associated with greater mortality after starting dialysis [13 && ]. It should be pointed out that most of these studies did not have a large population of patients receiving calcimimetics, and these drugs lower the serum calcium levels, and shift the set point of the calcium-PTH relationship to the left (PTH suppression at lower levels of calcium) [14] . Therefore, the use of these agents in CKD patients may alter the outcomes or the generalizability of these association studies.
Regulation of calcium homeostasis
In addition to the calcium self-regulation by the CaSR, other hormones that regulate calcium include PTH, vitamin D, and fibroblast growth factor-23 (FGF23). The primary function of PTH is to maintain blood ionized calcium levels by increasing bone mineral dissolution, thus releasing calcium and phosphate; increasing renal reabsorption of calcium and excretion of phosphate; increase the activity of the renal CYP27B1 (1-alpha-hydroxylase) enzyme to convert 25(OH)vitamin D to 1,25(OH) 2 D; and enhancing the gastrointestinal absorption of both calcium and phosphate, indirectly through its effects to increase 1,25(OH) 2 D. In healthy individuals, the increase in serum PTH concentration in response to hypocalcemia effectively restores serum calcium to normal levels. The loss of phosphate into the urine is compensated for by the enhanced bone resorption and indirect enhancement of intestinal phosphate absorption, thus maintaining normal serum phosphate levels. 
KEY POINTS
In CKD, calcium homeostasis is perturbed leading to abnormal calcium balance.
Tightly controlled balance studies demonstrate positive calcium balance in patients with CKD stage 3b/4 with oral intake of calcium from diet or binders of more than 800-1000 mg/day.
In patients with CKD, dietary calcium intake should be estimated by history to safely determine dosage of calcium-based binders that will not lead to positive calcium balance.
components of active calcium transport are upregulated by 1,25(OH) 2 D [17] . Mice with intestinal knock down of the vitamin D receptor (VDR) are still able to maintain normal calcium levels due to increased bone resorption. In contrast, global knock down of VDR leads to hypocalcemia, but this can also be corrected with a high calcium diet [18] .
FGF23 increases translocation of the calcium channel TRPV5 in the distal tubule [19] , thereby leading to low urine calcium levels which consequently affects calcium balance as detailed later. In addition, FGF23 likely has indirect effects on serum calcium levels. Studies in rats with CKD have demonstrated that calcium deficiency reduces circulating FGF23 [20] , and that the administration of calcium in drinking water increases FGF23 [21] . In CKD patients, the administration of calcitriol increases FGF23 [22] , whereas calcimimetics reduce FGF23 [23] . FGF23 also activates 24,25-hydroxylase (CYP24A1) [24] 
Calcium balance in health and chronic kidney disease
Calcium balance is determined by calcium intake minus calcium excretion in urine and feces. During bone growth in childhood, calcium balance is positive, providing the needed calcium to enhance skeletal growth. However, once peak bone mass is achieved at age 25-30 years, calcium balance becomes neutral in healthy individuals, with a slight negative balance around menopause [27] . The intricate regulators of calcium balance are similar to those regulators of calcium homeostasis, although bone released factors and gonadotropin hormones are also important.
In CKD, normal calcium balance is impaired. Studies in patients with CKD demonstrate that urinary calcium excretion levels fall as early as CKD stage 3 and remain extremely low. Although the initial thought was that this was due to PTH-induced calcium reabsorption, studies lowering PTH fail to change the urine calcium appreciably. More likely this is a result of altered regulation of the kidney TRPV5 channel in response to FGF23 [19] , acidosis, and calcium levels (reviewed in [28 && ]). Theoretically, the drop in urine calcium may be an appropriate compensation in CKD to maintain overall calcium balance in the setting of decreased intestinal calcium absorption due to decreased 1,25-vitamin D.
Balance studies are very complex and difficult to conduct. All techniques (Table 1) require steadystate calcium intake and are usually a crossover design to eliminate individual variability. Thus, a long-term accurate calcium balance study in patients on dialysis would have to accurately account for calcium flux removal (or retention) of calcium from the dialysate.
One of the earliest balance studies in patients with CKD was published in 1978. Doses of 47 Ca were ingested orally and injected intravenously. The fraction of calcium absorbed across the intestine was determined by measuring stool and urine calcium, demonstrating progressive drop in the fraction absorbed as creatinine clearance declined. Monthlong studies examining the whole body retention of 47 Ca demonstrated net increase in calcium retention in patients with creatinine clearances less than 40-50 ml/min [29] . The conclusion was that the vitamin D deficiency of CKD impaired intestinal absorption, and that the total body retention was predominately skeletal.
More recently, Spiegel et al. studied calcium balance in healthy individuals and in patients with CKD stage 3b/4. Two diets were compared: 800 and 2000-mg calcium, with diets prepared by clinical research study staff. Patients were given oral cholecalciferol for 1 month if baseline calcidiol levels were less than 30 ng/ml. They then had two diet periods of 9 days each in which subjects were given a standardized diet containing either the 800 or 2000-mg calcium diet (in a randomized crossover design). During the last 48 h of each 9-day period, subjects were admitted to the clinical research center and stool and urine collected. Balance was calculated as dietary intake À output (stool and urine). There was no difference in serum calcium or phosphorus levels, but a clear difference in calcium balance (Fig. 1) . Healthy individuals on the 800-mg diet were Double-isotope method (radiocalcium given orally and intravenously) with fecal and urinary recovery of radiocalcium in negative balance (net À144 AE 174), whereas the CKD patients were in neutral balance (net À91 AE 113). On the 2000-mg diet, both the groups were in positive calcium balance of 464 AE 225 mg in the healthy individuals and 759 AE 120 mg in the CKD patients. Thus, in patients with CKD, a daily dietary intake of approximately 800 mg maintains neutral calcium balance.
Our group conducted a balance study using a combination of oral and intravenous calcium radionuclides in patients with CKD stage 3b/4 to test the hypothesis that oral calcium carbonate of 500-mg elemental calcium leads to positive calcium balance [30] . All subjects took 1000 U of cholecalciferol for 14 days, and then were given 3 weeks of a standard diet of 1000-mg calcium with or without the 500-mg calcium binder with each of the three meals in a randomized crossover design. For the last 2 weeks of each 3-week period, subjects stayed in the clinical research center where urine and stool were collected for 14 days. The subjects were given both oral and intravenous 45 Ca and kinetic modeling done. The results (Fig. 2 ) demonstrated positive calcium balance when given the binder compared with placebo (average of 508 versus 61 mg/day, P ¼ 0.002) despite significant fecal excretion. The urine calcium excretion, even at this relatively early stage of CKD, was minimal. Similar to the study by Spiegel and Brady [31] , there was no difference in serum calcium levels during the two arms confirming the lack of relationship between serum calcium and calcium balance. Calcium kinetic modeling demonstrated that there was net positive 'bone' balance, indicating that 45 Ca stay in the extracellular space in either bone or soft tissue. These studies demonstrate that when CKD patients consume 800-1000 mg of dietary calcium, additional calcium in the form of binders leads to positive calcium balance.
Consequences of positive calcium balance
The above studies would suggest that additional calcium in the form of binders or supplements would be retained in CKD. Ideally, the calcium influx would be deposited in bone, but that assumes normal bone remodeling which is not present in CKD. Although calcium supplements are widely prescribed for bone health, in reality there is no evidence that additional calcium alone or in addition to an adequate dietary intake reduces fractures even in healthy individuals [32] . In patients with CKD, randomized trials of calcium containing phosphate binders versus noncalcium-containing phosphate binders have shown increased coronary artery calcification in most studies [33] [34] [35] but not all [36] . However, in most of these studies, there was also hypercalcemia and depressed PTH in the calcium binder treated patients. This does not allow for a determination of whether it is altered calcium homeostasis (hypercalcemia and altered hormone levels) or positive calcium balance that is the culprit in arterial or cardiac calcification.
We utilized a rat model of slowly progressive CKD to distinguish the role of hypercalcemia from positive calcium intake/load (equivalent to positive FIGURE 1. Estimated calcium balance in control and chronic kidney disease subjects on 800 and 2000-mg calcium diets. Filled circles, chronic kidney disease subjects; filled triangles, controls. Ca, calcium; Cont., control. Reproduced with permission [31] . calcium balance) on extraosseous calcification. In our Cy/þ rat model of progressive kidney disease, we treated rats with calcium in drinking water (to simulate increased oral intake/load), the calcimimetic R-568 (which lowers serum calcium levels), and R-568 and calcium (low serum calcium and calcium load) versus no treatment (normal calcium) [37] . The biochemical profile and magnitude of arterial and cardiac calcification are shown in Table 2 . Treatment with calcium in the drinking water led to increased thoracic aorta, heart, and aortic valve calcification regardless of the serum level of calcium (with or without R-568). Of interest, the calcium treatment led to an even greater calcification than observed with hyperphosphatemia and normal calcium levels in the R-568 þ calcium in the water treatment group [37] . These data suggest that positive calcium balance, regardless of whether hypercalcemia or hyperphosphatemia is present may induce ectopic calcification.
CONCLUSION
Calcium balance studies, due to their small sample size and crossover design, do not meet criteria for inclusion in clinical practice guidelines, but do form the basis for human recommended dietary intake. In the 2003 Kidney Disease Outcome Quality Improvment (K/DOQI) guidelines [38] , calcium intake from binder and diet was recommended to remain below 2500 mg/day, which was the Tolerable Upper Intake Levels for calcium established by the Food and Nutrition Board [39] . These guidelines were the first to suggest limiting calcium intake. In the Kidney Disease Improving Global Outcomes (KDIGO) guidelines of 2009 [40] , the recommendation was to 'restrict the dose of calcium-based phosphate binders and/or the dose of calcitriol or vitamin D analog in the presence of persistent or recurrent hypercalcemia (1B), arterial calcification and/or if serum PTH levels are persistently low (2B)'. In the KDIGO update of 2017 [41 & ], a more general recommendation (without caveats) was provided: 'in adult patients with CKD G3a-G5D receiving phosphatelowering treatment, we suggest restricting the dose of calcium-based phosphate binders (2B)'. KDIGO guidelines also noted that 'while the presence and severity of cardiovascular calcification strongly predict cardiovascular morbidity and mortality in patients with CKD, . . . there is limited evidence from RCTs in CKD that reduction of arterial calcification progression improves mortality'. There is also a lack of RCTs comparing high versus normal calcium balance on patient level outcomes. Thus, healthcare professionals need to individualize treatment approaches.
How much is too much? In a given patient, the dose of calcium-based phosphate binders that can be given without inducing positive calcium balance cannot be determined without a dietary history. A general guideline is that each serving of dairy is approximately 200 mg of calcium. Thus, if a patient eats four to five servings per day, they are getting the recommended intake of 800-1000 mg. However, as most patients with CKD are told to restrict phosphate intake, and thus avoid dairy products, most patients do not consume 800-1000 mg. A study of 128 hemodialysis patients indicated the average calcium intake was 372 AE 364 mg/day [42] , demonstrating the wide variability but generally low intake. Thus, dietary history is essential. The amount of calcium in each dose of calcium-based phosphate binder also differs: Each 667-mg calcium acetate contains 169 mg per pill of elemental calcium, whereas calcium carbonate of 1200 mg contains 500 mg per pill of elemental calcium depending on the manufacturer. Thus, a patient who consumes no calcium in the form of diet, four to five calcium acetate pills, or two calcium carbonate pills achieves the maximum calcium intake to . In summary, calcium is an essential ion and necessary to maintain good bone health and normal cellular physiology. During periods of bone growth in childhood, nature has devised an intricate homeostatic system that helps ensure positive calcium balance. Once in adulthood, those patients without kidney disease tend towards neutral balance. In the presence CKD, most patients will be in positive calcium balance when prescribed calcium-based binders with serum levels of calcium that may be low, normal, or high -the result of abnormal calcium homeostasis in kidney disease.
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